Volunteer for Research on Depression
in New York City.

---

Study One: Long Term Treatment of Major Depression:

All entering patients with Major Depression receive 12 weeks of open-label Prozac treatment, with no placebo. Responders are randomized to 1 year of maintenance or a switch to placebo. Relapsers during maintenance are removed from the study and given open treatment with Prozac if they relapsed on placebo and alternate pharmacotherapy if they relapsed on Prozac. Non-responders to Prozac will be given alternate antidepressants for up to 3 more months. Most patients with unipolar or bipolar 2 Major Depression without current alcohol or substance abuse are eligible. Previous Prozac treatment does not necessarily exclude potential subjects.

---

Patients who are currently abusing alcohol and also have a depressive disorder are eligible for a 12 week study of Prozac compared to placebo. All patients get weekly individual counseling using a behavioral model for controlling drinking. Responders get 6 months follow up treatment with medication provided. Non-responders to placebo at 12 weeks get a trial of Prozac; non-responders to Prozac get alternate pharmacologic treatment which may include ReVia (naltrexone) or other antidepressants. Most patients in generally good health who do not need inpatient detoxification are eligible.

To volunteer for either of these studies please contact:

Patrick J. McGrath, M.D.
New York State Psychiatric Institute
722 West 168th Street
New York, New York 10032
Phone: 212-960-5764
Fax: 212-960-2326
Email: PJM5@Columbia.edu

---

Lamotrigine for rapid cycling.

Bipolar outpatients with current major depression or rapid cycling (any phase) are needed to participate in a clinical trial of lamotrigine at the Payne Whitney Clinic of New York Hospital. The study is part of a multi-center nation-wide protocol assessing the efficacy and safety of lamotrigine for bipolar illness.

Appropriate subjects would be eligible to receive up to 1 year of free outpatient treatment with open-label lamotrigine after an initial several-week double-blind placebo-controlled phase.

For more information please contact either Joseph Goldberg, MD or Joy Whiteside, BA at the Mood Disorders Research Program of Payne Whitney Clinic-New York Hospital: (212) 821-0771.